Trial · NCT02429375
Adverse events87
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 87
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Neutrophil count decreased | Investigations | Dose Level 1: 50mg Mocetinostat | 0 | 3 | |
| other | Neutrophil count decreased | Investigations | Dose Level 2: 70mg Mocetinostat | 3 | 3 | |
| other | Neutrophil count decreased | Investigations | Dose Level 3: 90mg Mocetinostat | 1 | 1 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 1: 50mg Mocetinostat | 1 | 3 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Dose Level 1: 50mg Mocetinostat | 0 | 3 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Dose Level 3: 90mg Mocetinostat | 1 | 1 | |
| other | Nausea | Gastrointestinal disorders | Dose Level 1: 50mg Mocetinostat | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Nausea | Gastrointestinal disorders | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | Dose Level 1: 50mg Mocetinostat | 1 | 3 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Peripheral sensory neuropathy | Nervous system disorders | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Anorexia | Metabolism and nutrition disorders | Dose Level 1: 50mg Mocetinostat | 1 | 3 | |
| other | Anorexia | Metabolism and nutrition disorders | Dose Level 2: 70mg Mocetinostat | 0 | 3 | |
| other | Anorexia | Metabolism and nutrition disorders | Dose Level 3: 90mg Mocetinostat | 0 | 1 | |
| other | Cholesterol high | Investigations | Dose Level 1: 50mg Mocetinostat | 0 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02429375/events?page=2